Pinnamaneni Prasad, MD
Nephrology · Allen Park, MINPI 1821099045
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.3% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Bard Peripheral Vascular, Inc. accounts for 83.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $251 and has fallen 90.6% since, to $23 in 2025. That places this record below the midpoint for nephrology clinicians in MI, where the typical reported total is $606.
Across 20 payments — averaging $26.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$441
- Cordis US CORP.$43
- Akebia Therapeutics Inc$25
- Fresenius USA Marketing, Inc.$17
What the payments were for
- Food & beverage$50195%
- Education$255%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 16 | $441 |
| Cordis US CORP. | 2 | $43 |
| Akebia Therapeutics Inc | 1 | $25 |
| Fresenius USA Marketing, Inc. | 1 | $17 |
How this compares
$525 in reported general payments places this provider in the 45th percentile of 325 nephrology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cinacalcet Hcl | 13 | $20,277 |
| Sevelamer Carbonate | 27 | $6,533 |
| Calcium Acetate | 41 | $4,454 |
| Midodrine Hcl | 26 | $853 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 12 | $349 |
| Hydralazine Hcl | 17 | $345 |
| Calcitriol | 13 | $280 |
| Allopurinol | 41 | $205 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 12 | $115 |
| Furosemide | 12 | $61 |
| Hydroxyzine Hcl | 13 | $49 |
| Carvedilol | 11 | $26 |
| Prednisone | 12 | $14 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Allen Park
- Sudheer UmmadiAllen Park$9K
- Jeffrey GutmanAllen Park$6K
- Naushad PervezAllen Park$6K
- Alexander YevzlinAnn Arbor$1.1M
- Muwaffaq SalamehBay City$164K
- Laura MarianiAnn Arbor$150K
- Crystal Gardner-MartinLivonia$140K
- Katherine KwonSaint Joseph$111K
- Anatole BesarabDetroit$102K
- Richard CrossSaint Clair Shores$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.